Compare TCRT & HKPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TCRT | HKPD |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | Hong Kong |
| Employees | N/A | 27 |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Pharmaceuticals |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.7M | 6.9M |
| IPO Year | 2025 | N/A |
| Metric | TCRT | HKPD |
|---|---|---|
| Price | $2.63 | $0.56 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.1K | ★ 17.9K |
| Earning Date | 05-14-2026 | 08-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 24.66 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $15,900,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.67 | $0.37 |
| 52 Week High | $5.48 | $2.74 |
| Indicator | TCRT | HKPD |
|---|---|---|
| Relative Strength Index (RSI) | 38.01 | 38.37 |
| Support Level | $2.36 | $0.37 |
| Resistance Level | $2.84 | $0.71 |
| Average True Range (ATR) | 0.13 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 40.38 | 5.37 |
Alaunos Therapeutics Inc is a preclinical stage obesity and metabolic health drug development company that is aiming to develop a small molecule-based drug to treat obesity and other metabolic disorders that have a differentiated profile relative to currently marketed and in development oral and injectable products. The company focuses on evaluating the impact of ALN1001, its primary program, and its derivatives on lipid deposition and gene expression. It aims to develop an oral obesity compound that addresses many of the shortcomings of injectable GLP-1 receptor agonists including preserving lean muscle mass.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.